# A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)

> **NCT01105624** · PHASE4 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 50 (actual)

## Conditions studied

- Contact Lens Dry Eye

## Interventions

- **DRUG:** azithromycin ophthalmic solution, 1%
- **DRUG:** Visine® for Contacts®

## Key facts

- **NCT ID:** NCT01105624
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2011-09-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01105624

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01105624, "A Four Week Study of Azithromycin Ophthalmic Solution, 1% Versus Rewetting Drops in Subjects With History and Current Complaint of Contact Lens-Related Dry Eye (CLDE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01105624. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*